<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00633256</url>
  </required_header>
  <id_info>
    <org_study_id>0601001031</org_study_id>
    <nct_id>NCT00633256</nct_id>
  </id_info>
  <brief_title>The Effect of Cycloserine on Smoking Behavior in Nicotine Dependent Smokers</brief_title>
  <official_title>The Effect of Cycloserine on Smoking Behavior in Nicotine Dependent Smokers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VA Connecticut Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 20 subjects will participate in this four week, between groups, double-blind,
      placebo controlled study. Subjects will participate in two experimental sessions separated by
      approximately one week. Subjects will be randomized to receive either 50 mg cycloserine or
      placebo combined with cue exposure. Several physiological and subjective outcome measures
      (e.g., heart rate, blood pressure, galvanic skin response) will be obtained during the
      sessions. Experimental sessions will last approximately 4.5 hours with follow-up sessions
      lasting approximately thirty minutes. Our aims are:

        1. To examine the effect of cycloserine vs. placebo on extinction of smoking cue reactivity
           in overnight abstinent smokers. Reactivity to smoking cues will be captured with
           self-report smoking urges and physiological measures (heart rate, blood pressure, and
           skin conductance).

           We hypothesize that cycloserine, relative to placebo, will facilitate extinction of
           smoking cue reactivity.

        2. To examine the effect of cycloserine vs. placebo when combined with two 4.5 hour
           laboratory cue exposure training sessions, on smoking behavior in smokers. Smoking
           behavior will be measured with self-report smoking and saliva cotinine levels.

        3. To examine the effect of cycloserine vs. placebo on memory performance in nicotine
           dependent smokers. Memory performance will be measured with verbal learning, recognition
           and recall tasks.

      4) To examine the safety and tolerability of cycloserine treatment in smokers. We hypothesize
      that cycloserine will be well tolerated by smokers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cigarettes Smoked Per Day</measure>
    <time_frame>1 week follow-up</time_frame>
    <description>The number of cigarettes smoked per day at the 1 week follow up time point.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cigarettes Smoked Per Day</measure>
    <time_frame>4 Week Followup</time_frame>
    <description>The number of cigarettes smoked per day at the 4-week follow up timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Cotinine Level</measure>
    <time_frame>4 Week Follow-up Timepoint</time_frame>
    <description>Urinary Cotinine level at the 4-week follow up timepoint</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>Cycloserine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg cycloserine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Matched placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cycloserine</intervention_name>
    <description>50 mg Cycloserine given in two separate experimental sessions separated by approximately one week.</description>
    <arm_group_label>Cycloserine</arm_group_label>
    <other_name>Closina Aspen, Austral.</other_name>
    <other_name>Cycloserine Capsules USP 29</other_name>
    <other_name>Cycloserine (TM)King, UK</other_name>
    <other_name>D-cycloserin IFET (IFET), Gr.</other_name>
    <other_name>Proserine Hawon, Thai.</other_name>
    <other_name>Seromycin - 250 MG - Capsule Dura Pharmaceuticals</other_name>
    <other_name>Seromycin - 250 MG - Oral Capsule Eli Lilly</other_name>
    <other_name>Seromycin (FM) Lilly, Canad.</other_name>
    <other_name>Seromycin Dura, USA</other_name>
    <other_name>Seromycin Lilly, Hong Kong</other_name>
    <other_name>Seromycin With Isoniazid - 250 MG - Capsule Eli Lilly</other_name>
    <other_name>Siklocap</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo for subjects randomized to placebo arm. Given in two experimental sessions separated by approximately one week.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female and male smokers, aged 18 to 55 years;

          -  history of smoking daily for the past 12 months, at least 10 cigarettes daily;

          -  CO level &gt; 10ppm;

          -  for women: not pregnant as determined by pregnancy screening, nor breast feeding, and
             using acceptable birth control methods other than OCP;

          -  Non-treatment seeking nicotine dependent smokers.

        Exclusion Criteria:

          -  history of heart disease, renal or hepatic diseases or other medical conditions that
             the physician investigator deems as contraindicated for the patient to be in the
             study;

          -  regular use of psychotropic medication (antidepressants, antipsychotics, or
             anxiolytics) and/or recent psychiatric diagnosis and treatment for Axis I disorders
             including major depression, bipolar affective disorder, schizophrenia and panic
             disorder within the past year;

          -  current dependence on alcohol or on drugs other than nicotine;

          -  regular use of any other tobacco products than cigarettes, including smokeless tobacco
             and nicotine products;

          -  allergy to cycloserine;

          -  subjects with epilepsy or a history of seizures;

          -  Treatment seeking nicotine dependent smokers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Poling, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West Haven VA</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Santa Ana EJ, Rounsaville BJ, Frankforter TL, Nich C, Babuscio T, Poling J, Gonsai K, Hill KP, Carroll KM. D-Cycloserine attenuates reactivity to smoking cues in nicotine dependent smokers: a pilot investigation. Drug Alcohol Depend. 2009 Oct 1;104(3):220-7. doi: 10.1016/j.drugalcdep.2009.04.023. Epub 2009 Jul 9.</citation>
    <PMID>19592176</PMID>
  </reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 29, 2008</study_first_submitted>
  <study_first_submitted_qc>March 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2008</study_first_posted>
  <results_first_submitted>March 14, 2012</results_first_submitted>
  <results_first_submitted_qc>March 14, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 11, 2012</results_first_posted>
  <last_update_submitted>March 14, 2012</last_update_submitted>
  <last_update_submitted_qc>March 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>James Poling</investigator_full_name>
    <investigator_title>Research Scientist</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Cycloserine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cycloserine</title>
          <description>50 mg cycloserine</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matched placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cycloserine</title>
          <description>50 mg cycloserine</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matched placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.1" spread="6.2"/>
                    <measurement group_id="B2" value="41.5" spread="11.5"/>
                    <measurement group_id="B3" value="41.3" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cigarettes Smoked Per Day</title>
        <description>The number of cigarettes smoked per day at the 1 week follow up time point.</description>
        <time_frame>1 week follow-up</time_frame>
        <population>The number of participants used for analysis were those who completed the 4-week follow-up timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cycloserine</title>
            <description>50 mg cycloserine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Cigarettes Smoked Per Day</title>
          <description>The number of cigarettes smoked per day at the 1 week follow up time point.</description>
          <population>The number of participants used for analysis were those who completed the 4-week follow-up timepoint.</population>
          <units>Cigarettes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="6.3"/>
                    <measurement group_id="O2" value="13.9" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cigarettes Smoked Per Day</title>
        <description>The number of cigarettes smoked per day at the 4-week follow up timepoint.</description>
        <time_frame>4 Week Followup</time_frame>
        <population>The number of subjects in the study at the 4-week timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cycloserine</title>
            <description>50 mg cycloserine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Cigarettes Smoked Per Day</title>
          <description>The number of cigarettes smoked per day at the 4-week follow up timepoint.</description>
          <population>The number of subjects in the study at the 4-week timepoint.</population>
          <units>Cigarettes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" spread="7.7"/>
                    <measurement group_id="O2" value="11.0" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Cotinine Level</title>
        <description>Urinary Cotinine level at the 4-week follow up timepoint</description>
        <time_frame>4 Week Follow-up Timepoint</time_frame>
        <population>Subjects used for analysis are those who reached the 4 week followup timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cycloserine</title>
            <description>50 mg cycloserine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Cotinine Level</title>
          <description>Urinary Cotinine level at the 4-week follow up timepoint</description>
          <population>Subjects used for analysis are those who reached the 4 week followup timepoint.</population>
          <units>Mean ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1645.5" spread="1180.8"/>
                    <measurement group_id="O2" value="2062.6" spread="1091.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cycloserine</title>
          <description>50 mg cycloserine</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matched placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James Poling, Ph.D.</name_or_title>
      <organization>Yale University</organization>
      <phone>203-937-4830</phone>
      <email>james.poling@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

